GRAIL, Inc. (GRAL)
Market: NASD |
Currency: USD
Address: 1525 O’Brien Drive
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
📈 GRAIL, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$40.50
-
Upside/Downside from Analyst Target:
15.09%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
25-50%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for GRAIL, Inc.
| Date | Reported EPS |
|---|
| 2025-08-12 (estimated upcoming) | - |
| 2025-05-13 | -3.1 |
| 2025-02-20 | -2.89 |
| 2024-11-12 | -3.5 |
📰 Related News & Research
No related articles found for "grail inc".
